ATE388946T1 - Cyanamide als reversible hemmer von cystein proteasen - Google Patents
Cyanamide als reversible hemmer von cystein proteasenInfo
- Publication number
- ATE388946T1 ATE388946T1 AT03723865T AT03723865T ATE388946T1 AT E388946 T1 ATE388946 T1 AT E388946T1 AT 03723865 T AT03723865 T AT 03723865T AT 03723865 T AT03723865 T AT 03723865T AT E388946 T1 ATE388946 T1 AT E388946T1
- Authority
- AT
- Austria
- Prior art keywords
- cyanamide
- reversible inhibitor
- cystein proteases
- cysteine proteases
- proteases
- Prior art date
Links
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
- 239000013037 reversible inhibitor Substances 0.000 title 1
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 2
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000005600 Cathepsins Human genes 0.000 abstract 1
- 108010084457 Cathepsins Proteins 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C261/00—Derivatives of cyanic acid
- C07C261/04—Cyanamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37036802P | 2002-04-05 | 2002-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE388946T1 true ATE388946T1 (de) | 2008-03-15 |
Family
ID=29250518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03723865T ATE388946T1 (de) | 2002-04-05 | 2003-04-01 | Cyanamide als reversible hemmer von cystein proteasen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1495009B1 (de) |
| JP (1) | JP2005522489A (de) |
| AT (1) | ATE388946T1 (de) |
| AU (1) | AU2003230772A1 (de) |
| CA (1) | CA2477692A1 (de) |
| DE (1) | DE60319686T2 (de) |
| ES (1) | ES2301793T3 (de) |
| WO (1) | WO2003086325A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090005323A1 (en) * | 2005-01-19 | 2009-01-01 | Michael David Percival | Cathepsin K Inhibitors and Obesity |
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
| US10253027B2 (en) | 2013-07-08 | 2019-04-09 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| EP3292124B1 (de) | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridin- und benzo[c][1,7]naphthyridin-6-(5h)-on-verbindungen als inhibitoren der adapterassoziierten kinase 1 (aak1) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537293A (ja) * | 1999-02-20 | 2002-11-05 | アストラゼネカ アクチボラグ | カテプシンlおよび/またはカテプシンsの阻害剤としてのアセタミドアセトニトリル誘導体 |
| WO2001077073A1 (en) * | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
-
2003
- 2003-04-01 CA CA002477692A patent/CA2477692A1/en not_active Abandoned
- 2003-04-01 EP EP03723865A patent/EP1495009B1/de not_active Expired - Lifetime
- 2003-04-01 ES ES03723865T patent/ES2301793T3/es not_active Expired - Lifetime
- 2003-04-01 WO PCT/US2003/009852 patent/WO2003086325A2/en not_active Ceased
- 2003-04-01 AT AT03723865T patent/ATE388946T1/de not_active IP Right Cessation
- 2003-04-01 AU AU2003230772A patent/AU2003230772A1/en not_active Abandoned
- 2003-04-01 JP JP2003583350A patent/JP2005522489A/ja active Pending
- 2003-04-01 DE DE60319686T patent/DE60319686T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003086325A2 (en) | 2003-10-23 |
| ES2301793T3 (es) | 2008-07-01 |
| CA2477692A1 (en) | 2003-10-23 |
| EP1495009A2 (de) | 2005-01-12 |
| AU2003230772A8 (en) | 2003-10-27 |
| DE60319686D1 (de) | 2008-04-24 |
| WO2003086325A3 (en) | 2004-07-01 |
| JP2005522489A (ja) | 2005-07-28 |
| AU2003230772A1 (en) | 2003-10-27 |
| DE60319686T2 (de) | 2009-04-16 |
| EP1495009B1 (de) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE423108T1 (de) | Nitrile verwendbar als reversible cystein- protease inhibitoren | |
| AP1744A (en) | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | |
| MXPA04001016A (es) | Derivados de sulfonamida como inhibidores de la gamma secretasa. | |
| YU17003A (sh) | Spiroheterociklični nitrili upotrebljivi kao reverzibilni inhibitori cisteinskih proteaza | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| ATE516062T1 (de) | Quaternäre ammoniumverbindungen enthaltende wasserfreie zusammensetzungen | |
| MXPA05012268A (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa. | |
| EA200400815A1 (ru) | Контролируемый синтез зипразидона и его композиции | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| NO20030895D0 (no) | Ny anvendelse av dipeptidyl peptidase IV inhibitorer | |
| SE0201976D0 (sv) | Novel compounds | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| ATE450534T1 (de) | Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung | |
| EA200300970A1 (ru) | Энантиоселективный синтез промежуточных соединений для получения азетидинонов | |
| DE60319686D1 (de) | Cyanamide als reversible hemmer von cystein proteasen | |
| SG146658A1 (en) | Haloalkyl containing compounds as cysteine protease inhibitors | |
| ATE422501T1 (de) | Template-fixierte peptidomimetika als inhibitoren von serinproteasen | |
| DE60306934D1 (de) | Verwendung von Nitrilenverbindungen als Arztneimittel | |
| DE602004029355D1 (de) | Sulfopyrrolderivate | |
| EA200001152A1 (ru) | СУКЦИНАМИДНЫЕ ИНГИБИТОРЫ ИНТЕРЛЕЙКИН - 1b - КОНВЕРТИРУЮЩЕГО ФЕРМЕНТА | |
| ATE365702T1 (de) | Eisenoxide mit höherem veredelungsgrad | |
| ATE197591T1 (de) | 4-substituierte-3-peptidyl-azetidin-2-on-deriva e als cystein-proteinase inhibitoren | |
| WO2004110374A3 (en) | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | |
| MXPA04005988A (es) | 3,4-dihidro-1h-isoquinolin-2-il-derivados. | |
| ATE427934T1 (de) | Nicht-peptidische brs-3-agonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1495009 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |